FDA-Approved Heart Procedure Sparks Controversy

Medical professionals in an operating room monitoring a patient

A heart procedure that promises fewer burned organs, shorter time under anesthesia, and no esophageal fistulas sounds almost too good to be true — and the honest answer is that the jury is still deliberating.

Quick Take

Pulsed field ablation received Food and Drug Administration approval in early 2024 and uses electrical pulses instead of heat or cold to treat atrial fibrillation, reducing collateral damage to nearby structures like the esophagus and phrenic nerve.
Mayo Clinic had already treated more than 200 atrial fibrillation patients with the technology within months of its approval, calling it faster and safer than traditional thermal ablation.
The technology’s own proponents, including Mayo physicians, acknowledge it is not a cure, is only FDA-approved for one specific application, and that recurrence rates remain comparable to older methods.
Long-term durability data are still pending, meaning the most important question — does it keep atrial fibrillation away for years — remains unanswered.

What Traditional Ablation Actually Does to Surrounding Tissue

Atrial fibrillation ablation has been performed for decades using heat or cold energy to create tiny scars inside the heart that block the faulty electrical signals causing the irregular rhythm. ^[10] The problem is that the heart does not sit in isolation. The esophagus runs directly behind the left atrium, and the phrenic nerve, which controls the diaphragm, passes close by. Mayo Clinic electrophysiologist Dr. Suraj Kapa puts it plainly: traditional thermal approaches using radiofrequency, laser, and cryo energy all carry an associated injury risk to those nearby structures. ^[1] That risk is not theoretical — esophageal injury from ablation can be fatal.

How Pulsed Field Ablation Changes the Physics of the Procedure

Pulsed field ablation delivers short, high-voltage electrical pulses rather than sustained thermal energy. The mechanism is called irreversible electroporation, which disrupts cell membranes in cardiac tissue and causes cell death without generating the sustained heat that damages adjacent structures. ^[1] The key word is selectivity. Cardiac muscle cells appear more vulnerable to this type of energy than esophageal tissue or nerve tissue, which is the biological basis for the safety claim. ^[3] That selectivity is real and mechanistically sound, but whether it fully eliminates adjacent-structure risk in every clinical scenario across every operator skill level is a different question.

The Food and Drug Administration approved pulsed field ablation for pulmonary vein isolation — the specific procedure used to treat atrial fibrillation — and Mayo Clinic began using it in February 2024. ^[2] Within months, its cardiac specialists had treated more than 200 atrial fibrillation patients with the technology. ^[2] Mayo also reports that the procedure can run faster and may reduce the time a patient spends under anesthesia, which matters considerably for older patients or those with other health conditions. ^[2] Studies suggest roughly 65 to 75 percent of patients remain free of atrial fibrillation one year after the procedure, a figure consistent with traditional ablation. ^[4]

The Limitation Mayo’s Own Physicians Are Candid About

Here is where intellectual honesty demands a pause. Mayo’s own specialists state clearly that pulsed field ablation is not a definitive cure for atrial fibrillation and that radiofrequency ablation remains an essential tool, with pulsed field ablation complementing rather than replacing it. ^[3] More striking still, a 2025 Mayo podcast on the subject acknowledges that post-ablation recurrences are comparable to previously established modalities and describes this as a significant hurdle that has yet to be overcome. ^[7] That admission comes from the institution most visibly promoting the technology, which gives it considerable credibility.

What Patients Over 40 With Atrial Fibrillation Should Actually Do With This Information

Atrial fibrillation is a chronic disease requiring broad management — stroke prevention, rate control, rhythm control — and ablation is one component of that picture, not a standalone fix. ^[6] Pulsed field ablation appears to be a genuine procedural improvement in terms of how the energy is delivered and what it spares, but the durability question is the one that matters most to a 55-year-old deciding whether to have the procedure. Long-term outcome data are still pending. ^[3] That is not a reason to refuse the procedure, but it is a reason to ask your electrophysiologist exactly what the one-year and three-year recurrence data look like at their specific center before agreeing to anything.

The honest framing here is that pulsed field ablation represents a meaningful mechanical advance with a sound biological rationale, early safety signals that are genuinely encouraging, and an efficiency profile that benefits patients in real ways. What it does not yet have is the long-horizon evidence that would justify calling it superior to established methods on the outcome that patients care about most: staying out of atrial fibrillation for years, not months. The technology is promising. Promising is not the same as proven, and anyone telling you otherwise — institution or device manufacturer — is getting ahead of the data.